Vaccinex Sees Mixed Signals In Huntington’s Study

Pepinemab Missed Key Endpoints In Phase II Trial

22 Sep 2020

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Hand flip wooden cube with the word PLAN A to PLAN B on white background. Business concept — With mixed data in Huntington's, Vaccinex turns attention to Alzheimer's

Vaccinex, Inc.’s potentially disease-modifying therapy for Huntington’s disease missed its key endpoints in top-line data unveiled 22 September from the Phase II SIGNAL study, but the biotech thinks the novel drug offers potential in both Alzheimer’s disease and also later-stage Huntington’s patients than those included in the trial.

The company noted that in cohort B1 of SIGNAL – testing the semaphorin 4D (SEMA4D) inhibitor pepinemab in 179 early...